‘Strategic Decision’ Prompts Janssen Exit From Chi-Med Deal
This article was originally published in PharmAsia News
Executive Summary
One of the largest collaborative deals in China’s pharmaceutical industry has fallen apart, as Janssen has opted to terminate an R&D alliance agreement in the inflammation/immunology area with Hutchison China MediTech, although the two firms intend to continue to work together in other areas.